Cyclo Therapeutics Inc (CYTH)

$0.72 +0.01 (1.39%)
Market Cap 23.72M
Revenue (ttm) 1.08M
Net Income (ttm) -20.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,857.41%
Debt to Equity Ratio 0.00
Volume 188,200
Avg Vol 1,832,044
Day's Range N/A - N/A
Shares Out 32.92M
Stochastic %K 74%
Beta -0.57
Analysts Sell
Price Target $0.95
Biotechnicity
Biotechnicity Jul. 27 at 8:20 PM
$RFL Another bad sign is that the half dozen or so regular posters on the $CYTH board (OCBadger; MWT; et al) are strangely quiet or missing altogether on this one. And their comments, when made, are quite passive. Almost conciliatory. It was one thing to pump this compound and trial from $22 a share to pocket change before the acquisition burying it beneath a “real estate” holding company but, perhaps, they’ve been instructed not to do it again because a) the data is good? or b) the data is bad? Which makes more sense? Release the data before an equity raise Mr. Jonas. Not after! If that happens we know why they’re missing in action. I kinda already do.
3 · Reply
Biotechnicity
Biotechnicity Jul. 26 at 11:07 PM
$ZVRA After FDA felt political pressure leading to Sarepta’s eteplirsen approval in which the sponsor refused to conduct a legit trial — and while in the midst of helping Orphazyme cobble together a stat-sig Phase 2/3 arimoclomol study by identifying 2-patients unresponsive to therapy and wondering where missing data from 4-patients was (SAE’s provoking the disappearance?) — they were working with $CYTH (now $RFL) on designing a study that would prove whether or not Trappsol-Cyclo was a safe & effective therapy for NPC patients. It is almost twice as large (104-patients). It is robust with well designed endpoints. And, given the problematic history of eteplirsen and arimoclomol, was unpartnered. No one believed such a study could readout stat-sig. I still don’t. But neither did FDA which simply asked for a study that could adequately demonstrate a relationship between therapy and the targeted outcome. Completely unfair to the new sponsor, Raphael! But a study embraced by FDA & EMA.
4 · Reply
Biotechnicity
Biotechnicity Jul. 13 at 10:52 PM
$RFL Our only catalyst is CHMP’s rejection of the arimoclomol application by the end of July - September the odds of which increased after YARTEMLEA’s rejection in June. We saw a little disturbance of the topsoil in early trading today. Most everyone realizes the odds of TRANSPORT statistical success on the primaries is virtually nonexistent. The reasons are obvious. ▪️Big Pharma disinterest [evidenced by no partner] ▪️General market disinterest evidenced by the crashing share price of $CYTH from $22 to pocket change ▪️Failure to release Topline data as promised in 2025 ▪️This message board 🤣 Raphael desperately needs to shift the focus of the traditional investor to a new paradigm in rare disease studies - A well designed and executed trial in consultation with regional agencies that demonstrates an effective relationship between the MOA and targeted gene. ✔️ Arimoclomol’s rejection in the EU will reinforce that shift and be prominently featured in the TRANSPORT press release. ✔️
3 · Reply
Biotechnicity
Biotechnicity Jul. 6 at 11:00 PM
If Google is right, it appears CEO Howard Jonas offloaded nearly 5m of his free shares in Raphael for $15M or so. Why free? In 2025 he was accredited with purchasing far more than that in $RFL during the merger with $CYTH which appeared bullish, yet, he admitted to not using his own money but, instead, using shares acquired in Cyclo Therapeutics during his “financing” of their operations which gave the appearance of bullishness. However, let’s focus on today as that’s all we have. Other explanations for his reduced stake here could be that… 1. Google made a mistake! And he still owns 19m shares. 2. The shares weren’t sold but transferred to a private party such as a family member. This wouldn’t require a S-4. 3. The shares weren’t sold but transferred to a buyer of one of his subsidiaries. If true, we could be receiving a PR about one or more of his subsidiaries being sold for in excess of the amount transferred to them in $RFL shares. Wishful thinking perhaps but possible.
2 · Reply
Biotechnicity
Biotechnicity Jul. 2 at 2:47 PM
$RFL Allow me to dispel of few long myths on any board. #1 That CEO’s have a fiduciary responsibility to their investors. This one is so silly it makes me double over with laughter. Was it Scott Fines “fiduciary obligation” to secure a partner BEFORE running a large, phase-3 registration trial? Of course it was! Did he? No, he did not! #2 That by locking up our shares by using high limit orders, traders can’t use them to short the same stock we are long in. I do it all the time knowing full well it doesn’t matter. Naked shorting and dark pool trading suggests it’s almost as valid as big foot is real. And what about Howard’s 19.18 million shares? Are they unavailable to his Wall Street buddies? And how in the hell did he get that basket of common shares in the first place? Ah, those predatory financings of Scott Fines share printing racket known as $CYTH. Cut the crap! Put down the pom-poms and start thinking people! Still…
0 · Reply
Biotechnicity
Biotechnicity Jul. 2 at 1:58 PM
$AMRN $CYTH $ZVRA I’m extremely close to closing my position here in $RFL Once the idiot longs return with their parked I.D.’s we know the hedge funds are locked and loaded to go short behind them because that’s where the money is — going short. P-3 data here is likely NOT STAT-SIG. However, as I’ve repeatedly suggested it DOESN’T HAVE TO BE. It’s not even the primary catalyst that has moved this share price sky high over the past month. I can support every facet of the above statement with TANGIBLE FACTS. Can you support the argument against that with something other than the “Beautiful Molecule” theory or the “they waited at 48-Weeks because the data was so good” nonsense/some sense theory? Please stop! Go back to sleep Cythians before the color we see today becomes the color we see everyday. I’m seeing red just responding to your passive rage.
0 · Reply
SinfulMeatStick
SinfulMeatStick Sep. 17 at 4:14 PM
$CYTH why is everyone still posting here? Cyth is now $RFL
1 · Reply
DottoreMK
DottoreMK May. 9 at 4:16 PM
$CYTH
0 · Reply
Miko_Vakilla
Miko_Vakilla Apr. 7 at 8:39 PM
$CYTH Form 15! $2.15 here we come. Let's go Mo!
1 · Reply
GDS_investing
GDS_investing Apr. 7 at 6:06 PM
$RFL money on the floor add here today for 5$+ $CYTH
0 · Reply
Latest News on CYTH
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Feb 20, 2025, 4:35 PM EST - 1 year ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

RFL

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Feb 7, 2025, 8:05 AM EST - 1 year ago

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

Jan 14, 2025, 8:05 AM EST - 1 year ago

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

Dec 20, 2024, 12:15 PM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

SKGR

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

Nov 21, 2024, 4:13 AM EST - 1 year ago

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 8:05 AM EST - 1 year ago

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Sep 5, 2024, 9:05 AM EDT - 2 years ago

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Aug 22, 2024, 10:19 AM EDT - 2 years ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

RFL

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 2 years ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

RFL

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 9:00 AM EDT - 2 years ago

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Jul 29, 2024, 9:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Jun 25, 2024, 9:25 AM EDT - 2 years ago

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

May 30, 2024, 9:00 AM EDT - 2 years ago

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 9:05 AM EDT - 2 years ago

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Mar 14, 2024, 9:34 AM EDT - 2 years ago

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Jan 29, 2024, 9:15 AM EST - 2 years ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Dec 27, 2023, 4:15 PM EST - 2 years ago

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Dec 18, 2023, 9:15 AM EST - 2 years ago

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Nov 28, 2023, 5:19 PM EST - 2 years ago

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Nov 21, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Nov 15, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Oct 23, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Oct 5, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Sep 21, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Aug 15, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Aug 2, 2023, 8:16 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

RFL

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Jun 29, 2023, 1:32 PM EDT - 3 years ago

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Jun 12, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Jun 5, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

RFL

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 15, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

May 2, 2023, 8:12 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

RFL

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 21, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Mar 20, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Jan 11, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Jan 10, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Jan 9, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 4, 2023, 4:05 PM EST - 3 years ago

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Jan 4, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Dec 30, 2022, 8:00 AM EST - 3 years ago

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Nov 11, 2022, 8:05 AM EST - 4 years ago

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Oct 18, 2022, 8:05 AM EDT - 4 years ago

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Oct 4, 2022, 8:05 AM EDT - 4 years ago

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Cyclo Therapeutics Provides Business Update

Sep 28, 2022, 2:02 PM EDT - 4 years ago

Cyclo Therapeutics Provides Business Update

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 8:05 AM EDT - 4 years ago

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 16, 2022, 8:05 AM EDT - 4 years ago

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Cyclo Therapeutics to Present at the China NPC Association Meeting

Aug 8, 2022, 8:05 AM EDT - 4 years ago

Cyclo Therapeutics to Present at the China NPC Association Meeting

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Jul 21, 2022, 8:05 AM EDT - 4 years ago

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Biotechnicity
Biotechnicity Jul. 27 at 8:20 PM
$RFL Another bad sign is that the half dozen or so regular posters on the $CYTH board (OCBadger; MWT; et al) are strangely quiet or missing altogether on this one. And their comments, when made, are quite passive. Almost conciliatory. It was one thing to pump this compound and trial from $22 a share to pocket change before the acquisition burying it beneath a “real estate” holding company but, perhaps, they’ve been instructed not to do it again because a) the data is good? or b) the data is bad? Which makes more sense? Release the data before an equity raise Mr. Jonas. Not after! If that happens we know why they’re missing in action. I kinda already do.
3 · Reply
Biotechnicity
Biotechnicity Jul. 26 at 11:07 PM
$ZVRA After FDA felt political pressure leading to Sarepta’s eteplirsen approval in which the sponsor refused to conduct a legit trial — and while in the midst of helping Orphazyme cobble together a stat-sig Phase 2/3 arimoclomol study by identifying 2-patients unresponsive to therapy and wondering where missing data from 4-patients was (SAE’s provoking the disappearance?) — they were working with $CYTH (now $RFL) on designing a study that would prove whether or not Trappsol-Cyclo was a safe &amp; effective therapy for NPC patients. It is almost twice as large (104-patients). It is robust with well designed endpoints. And, given the problematic history of eteplirsen and arimoclomol, was unpartnered. No one believed such a study could readout stat-sig. I still don’t. But neither did FDA which simply asked for a study that could adequately demonstrate a relationship between therapy and the targeted outcome. Completely unfair to the new sponsor, Raphael! But a study embraced by FDA &amp; EMA.
4 · Reply
Biotechnicity
Biotechnicity Jul. 13 at 10:52 PM
$RFL Our only catalyst is CHMP’s rejection of the arimoclomol application by the end of July - September the odds of which increased after YARTEMLEA’s rejection in June. We saw a little disturbance of the topsoil in early trading today. Most everyone realizes the odds of TRANSPORT statistical success on the primaries is virtually nonexistent. The reasons are obvious. ▪️Big Pharma disinterest [evidenced by no partner] ▪️General market disinterest evidenced by the crashing share price of $CYTH from $22 to pocket change ▪️Failure to release Topline data as promised in 2025 ▪️This message board 🤣 Raphael desperately needs to shift the focus of the traditional investor to a new paradigm in rare disease studies - A well designed and executed trial in consultation with regional agencies that demonstrates an effective relationship between the MOA and targeted gene. ✔️ Arimoclomol’s rejection in the EU will reinforce that shift and be prominently featured in the TRANSPORT press release. ✔️
3 · Reply
Biotechnicity
Biotechnicity Jul. 6 at 11:00 PM
If Google is right, it appears CEO Howard Jonas offloaded nearly 5m of his free shares in Raphael for $15M or so. Why free? In 2025 he was accredited with purchasing far more than that in $RFL during the merger with $CYTH which appeared bullish, yet, he admitted to not using his own money but, instead, using shares acquired in Cyclo Therapeutics during his “financing” of their operations which gave the appearance of bullishness. However, let’s focus on today as that’s all we have. Other explanations for his reduced stake here could be that… 1. Google made a mistake! And he still owns 19m shares. 2. The shares weren’t sold but transferred to a private party such as a family member. This wouldn’t require a S-4. 3. The shares weren’t sold but transferred to a buyer of one of his subsidiaries. If true, we could be receiving a PR about one or more of his subsidiaries being sold for in excess of the amount transferred to them in $RFL shares. Wishful thinking perhaps but possible.
2 · Reply
Biotechnicity
Biotechnicity Jul. 2 at 2:47 PM
$RFL Allow me to dispel of few long myths on any board. #1 That CEO’s have a fiduciary responsibility to their investors. This one is so silly it makes me double over with laughter. Was it Scott Fines “fiduciary obligation” to secure a partner BEFORE running a large, phase-3 registration trial? Of course it was! Did he? No, he did not! #2 That by locking up our shares by using high limit orders, traders can’t use them to short the same stock we are long in. I do it all the time knowing full well it doesn’t matter. Naked shorting and dark pool trading suggests it’s almost as valid as big foot is real. And what about Howard’s 19.18 million shares? Are they unavailable to his Wall Street buddies? And how in the hell did he get that basket of common shares in the first place? Ah, those predatory financings of Scott Fines share printing racket known as $CYTH. Cut the crap! Put down the pom-poms and start thinking people! Still…
0 · Reply
Biotechnicity
Biotechnicity Jul. 2 at 1:58 PM
$AMRN $CYTH $ZVRA I’m extremely close to closing my position here in $RFL Once the idiot longs return with their parked I.D.’s we know the hedge funds are locked and loaded to go short behind them because that’s where the money is — going short. P-3 data here is likely NOT STAT-SIG. However, as I’ve repeatedly suggested it DOESN’T HAVE TO BE. It’s not even the primary catalyst that has moved this share price sky high over the past month. I can support every facet of the above statement with TANGIBLE FACTS. Can you support the argument against that with something other than the “Beautiful Molecule” theory or the “they waited at 48-Weeks because the data was so good” nonsense/some sense theory? Please stop! Go back to sleep Cythians before the color we see today becomes the color we see everyday. I’m seeing red just responding to your passive rage.
0 · Reply
SinfulMeatStick
SinfulMeatStick Sep. 17 at 4:14 PM
$CYTH why is everyone still posting here? Cyth is now $RFL
1 · Reply
DottoreMK
DottoreMK May. 9 at 4:16 PM
$CYTH
0 · Reply
Miko_Vakilla
Miko_Vakilla Apr. 7 at 8:39 PM
$CYTH Form 15! $2.15 here we come. Let&#39;s go Mo!
1 · Reply
GDS_investing
GDS_investing Apr. 7 at 6:06 PM
$RFL money on the floor add here today for 5$+ $CYTH
0 · Reply
StreetSlap
StreetSlap Apr. 6 at 7:03 AM
$ANVS $CYTH $CEIN $IMUX $PTPI Lol Nah...great retail hunters, great scammers, but Maria just set the bar to a new low 🐍💃🏻
1 · Reply
ForestFoxes
ForestFoxes Apr. 6 at 12:27 AM
$ANVS $CYTH $CEIN $IMUX $PTPI @StreetSlap🤯 ⁿᵒ ʷᵃʸ ... 🤨 ᵃʳᵉ ʸᵒᵘ ᵗᵉˡˡᶦⁿᵍ ᵐᵉ ᵗʰᵃᵗ ᵗʰᵒˢᵉ ᶜᴱᴼˢ ... ᵃˡˢᵒ ʰᵉˡᵈ ᵃ ᴾᵃᵗᶦᵉⁿᵗˢ&#39; ᴸᶦᵛᵉ ᶠᵒʳᵘᵐ and, told patients and their families to &quot;BUY Stock!&quot; and &quot;That&#39;s the ONLY out of it!&quot; 💔 Did those other CEOs also use fiery language in their chat with patients and families with references to Hell repeated??? 🔥🐍😈🔥
1 · Reply
StreetSlap
StreetSlap Apr. 5 at 9:56 PM
$ANVS Golden rule ! Saw that so many times...$CYTH (Scott Fine) $CEIN (James Doris) $IMUX (Daniel Vitt) $PTPI (Fady Boctor) just to name a few
0 · Reply